709 results on '"Mulligan, Mark J."'
Search Results
2. Generation of quality-controlled SARS-CoV-2 variant stocks
3. Multimodal single-cell datasets characterize antigen-specific CD8+ T cells across SARS-CoV-2 vaccination and infection
4. Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial
5. Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants
6. The immunodominance of antigenic site Sb on the H1 influenza virus hemagglutinin increases with high immunoglobulin titers of the cohorts and with young age, but not sex
7. Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine
8. Immunogenicity and safety of varying dosages of a fifth-wave influenza A/H7N9 inactivated vaccine given with and without AS03 adjuvant in healthy adults
9. mRNA COVID-19 vaccine elicits potent adaptive immune response without the acute inflammation of SARS-CoV-2 infection
10. Natural infection by Zika virus but not DNA vaccination consistently elicits antibodies that compete with two potently neutralising monoclonal antibodies targeting distinct epitopes
11. Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trials
12. Author Correction: Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials
13. Selective adaptation of SARS-CoV-2 Omicron under booster vaccine pressure: a multicentre observational study
14. Distinct cellular immune properties in cerebrospinal fluid are associated with cognition in HIV-infected individuals initiating antiretroviral therapy
15. COVID-19 booster vaccination during pregnancy enhances maternal binding and neutralizing antibody responses and transplacental antibody transfer to the newborn
16. Matrix lumican endocytosed by immune cells controls receptor ligand trafficking to promote TLR4 and restrict TLR9 in sepsis
17. Emergence and dissemination of SARS-CoV-2 XBB.1.5 in New York
18. Longitudinal study of immunity to SARS‐CoV2 in ocrelizumab‐treated MS patients up to 2 years after COVID‐19 vaccination
19. A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered with and without AS03 Adjuvant in Healthy US Adults
20. Knowledge and Attitudes Toward Covid-19 and Vaccines Among a New York Haredi-Orthodox Jewish Community
21. A Repurposed Drug Interferes with Nucleic Acid to Inhibit the Dual Activities of Coronavirus Nsp13.
22. SARS-CoV-2 inflammation durably imprints memory CD4 T cells.
23. A High Throughput Whole Blood Assay for Analysis of Multiple Antigen-Specific T Cell Responses in Human Mycobacterium tuberculosis Infection
24. Partial resistance of SARS-CoV-2 Delta variants to vaccine-elicited antibodies and convalescent sera
25. Antibody Titers against Mpox Virus after Vaccination
26. Adjuvanted H5N1 influenza vaccine enhances both cross-reactive memory B cell and strain-specific naive B cell responses in humans
27. Decreased humoral immunity to mumps in young adults immunized with MMR vaccine in childhood
28. The New York State SARS-CoV-2 Testing Consortium: Regional Communication in Response to the COVID-19 Pandemic
29. Maternal COVID-19 Vaccination and Prevention of Symptomatic Infection in Infants.
30. Antibody isotype diversity against SARS-CoV-2 is associated with differential serum neutralization capacities
31. Author Correction: Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials
32. Immunologic mechanisms of seasonal influenza vaccination administered by microneedle patch from a randomized phase I trial
33. Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials
34. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
35. Phase 1 Open-Label Dose Escalation Trial for the Development of a Human Bacillus Calmette-Guérin Challenge Model for Assessment of Tuberculosis Immunity In Vivo
36. 1629. Acceptability and Trust in the Low-dose Intradermal Mpox Vaccine: a Knowledge, Attitudes and Practices Sub-analysis of the Observational Study of Mpox Immunity (OSMI) in NYC
37. 462. Infant antibody titers at birth following maternal COVID-19 vaccination and protection against infection in the first 6 months of life
38. 1495. Mpox Vaccine Immunity in People Living with HIV (PLWH) During The 2022 Mpox Outbreak in New York City
39. Immune response, phenotyping and molecular graft surveillance in kidney transplant recipients following severe acute respiratory syndrome coronavirus 2 vaccination
40. Blockade Antibody Responses in Human Subjects Challenged with a New Snow Mountain Virus Inoculum
41. Theory-Based Analysis of Interest in an HIV Vaccine for Reasons Indicative of Risk Compensation among African American Women
42. Identification of immunodominant T cell epitopes induced by natural Zika virus infection
43. Measurement of Human Immunodeficiency Virus p24 Antigen in Human Cerebrospinal Fluid With Digital Enzyme-Linked Immunosorbent Assay and Association With Decreased Neuropsychological Performance
44. Theory-Based Analysis of Interest in an HIV Vaccine for Reasons Indicative of Risk Compensation Among African American Women
45. Varicella-Zoster Virus DNA in Blood After Administration of Herpes Zoster Vaccine
46. Innate, T-, and B-Cell Responses in Acute Human Zika Patients
47. Caregiver and adolescent factors associated with delayed completion of the three-dose human papillomavirus vaccination series
48. Antibody responses among adolescent females receiving two or three quadrivalent human papillomavirus vaccine doses at standard and prolonged intervals
49. Randomized clinical trial of a single versus a double dose of 13-valent pneumococcal conjugate vaccine in adults 55 through 74 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine
50. Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.